Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RCUS
Strong SellHot AirArcus Biosciences, Inc. · Healthcare · United States · $3.7B · Avg Vol: $32M/d
COMPANY DESCRIPTION
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies, targeting critical pathways in immuno-oncology. It specializes in developing small molecule and antibody therapeutics, often pursuing combination strategies to enhance treatment efficacy. Operating in the high-growth immuno-oncology space, Arcus frequently collaborates with larger pharmaceutical companies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 112.0M | 117.0M | 258.0M | 247.0M | 30.2% | 117.0M | 78.6M | 52.1M | -54.1% |
| EPS | -3.71 | -4.15 | -3.14 | -3.29 | — | -3.94 | -3.53 | -3.34 | — |
| Shares | 72.9M | 75.5M | 92.2M | 125.3M | +71.9% | 125.8M | — | — | — |
| Debt | 3.0M | 11.0M | 60.0M | 112.0M | 234.2% | 238.0M | — | — | — |
| Equity | 657.0M | 462.0M | 485.0M | 631.0M | -1.3% | — | — | — | — |
| Op CF | 438.0M | -306.0M | -170.0M | -482.0M | — | -474.0M | — | — | — |
| Inv CF | -413.0M | 194.0M | -84.0M | 66.0M | — | — | — | — | — |
| Fin CF | 33.0M | 33.0M | 277.0M | 488.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RCUS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RCUS | Arcus Biosciences, Inc.(you) | $3.7B | 14 | Strong Sell |
| GPCR | Structure Therapeutics Inc. | $3.4B | 13 | Strong Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
| BEAM | Beam Therapeutics Inc. | $3.0B | 13 | Strong Sell |
| VKTX | Viking Therapeutics, Inc. | $3.8B | 18 | Strong Sell |
| DYN | Dyne Therapeutics, Inc. | $4.7B | 13 | Strong Sell |
| CELC | Celcuity Inc. | $4.3B | 10 | Strong Sell |
| DNLI | Denali Therapeutics Inc. | $3.8B | 21 | Sell |
| IDYA | IDEAYA Biosciences, Inc. | $3.9B | 21 | Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%